Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887844 | 1.00 | KMT2A (0.44) | KMT2AGAAHPGDERBB2DDB1 | |
| SCHEMBL30051336 | 0.87 | KMT2A (0.41) | KMT2AGAAHPGDERBB2DDB1 | |
| SCHEMBL24809172 | 0.87 | KMT2A (0.41) | KMT2AGAAHPGDERBB2DDB1 | |
| SCHEMBL31475832 | 0.85 | FGFR1 (0.34) | KMT2AGAAHPGDERBB2ALDH1A1 | |
| SCHEMBL30050420 | 0.83 | GRM5 (0.42) | ERBB2GRM5 | |
| SCHEMBL24807701 | 0.83 | GRM5 (0.42) | ERBB2GRM5 | |
| SCHEMBL24809164 | 0.82 | BRAF (0.34) | ERBB2 | |
| SCHEMBL30050974 | 0.82 | BRAF (0.34) | ERBB2 | |
| SCHEMBL24569747 | 0.81 | KMT2A (0.43) | KMT2AGAAHPGDERBB2DDB1 | |
| SCHEMBL1191996 | 0.81 | KMT2A (0.46) | KMT2AGAAHPGDERBB2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023185793-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | KMT2A 778/4885GAA 1431/4885HPGD 2596/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | KMT2A 1686/4885GAA 1555/4885HPGD 1254/4885 |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | KMT2A 899/4885GAA 1095/4885HPGD 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.